Global Transdermal Patch Market & Pipeline Insight 2015
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Technological progress is continuously increasing allowing pharmaceutical companies to develop newer products with higher pharmacological benefits. Transdermal patches are extension of their continuous efforts due to which several patients have been able to improve quality of life. This market segment has yet to be tapped as only few disease indications are being covered under their treatment. Pharmaceutical companies are increasing their investments in research and development segment to introduce novel products in market. Significant progress has been made in past several decades giving rise to presence of myriad of products in global market. They are far better than their predecessors and coming products are expected to be better than existing transdermal patches. As a result, more number of patients are expected to be opting for transdermal patches in their therapeutic regime.
Utilization of transdermal patch varies from region to region due to which their market is diffused in nature. In both industrially developed and under developed countries their consumption is increasing significantly in past few years. US is one of the largest transdermal patch market across the globe followed by Europe. Investment in research and development allows the continuous entry of new products in US market due to which it has largest market shares across the globe. It is pioneer in this field and first patch was introduced in 1979 to treat motion sickness after its wide spread acceptance patches for angina, high blood pressure and hormone replacement therapy were introduced in US market. Over the year newer categories like smoking cessation, pain management, Parkinson’s disease, Alzheimer’s disease, ADHD and may others disease indications were added resulting in increased market size.
Clinical pipeline for transdermal patches is becoming strong and various novel therapeutics are at different stages of clinical trials which would enter in market in coming years. It is happening because pharmaceutical companies have identified their commercial potential due to which they are investing more toward research and development segment. Orally administrated drugs are not suitable for all patients as they have gastric reflex problem or may have other gastrointestinal diseases due to which bioavailability is limited. On the other, in blood they may interact with other substance causing reduced pharmacological effects. All these problems are not encountered by patients using the transdermal patches.
New principles are being deciphered and increasing emphasis on including more diseases treatment by transdermal patches is imperative for better health. Owing to increasing disease incidences, it has become necessary to take necessary steps to introduce innovative transdermal patches in global market. Oncology and autoimmune diseases are still untouched by them due to which significant opportunities are left untapped. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. On the other hand, nicotine patches and female contraceptive patches are highly developed and forms largest categories of transdermal patch segment. Disease indications will be increased in coming years and advancements in polymer science is expected to increase the innovation rates. With all these developments, the future of transdermal patch market seems to be optimistic.
“Global Transdermal Patch Market & Pipeline Insight 2015” Report Highlights:
Technological progress is continuously increasing allowing pharmaceutical companies to develop newer products with higher pharmacological benefits. Transdermal patches are extension of their continuous efforts due to which several patients have been able to improve quality of life. This market segment has yet to be tapped as only few disease indications are being covered under their treatment. Pharmaceutical companies are increasing their investments in research and development segment to introduce novel products in market. Significant progress has been made in past several decades giving rise to presence of myriad of products in global market. They are far better than their predecessors and coming products are expected to be better than existing transdermal patches. As a result, more number of patients are expected to be opting for transdermal patches in their therapeutic regime.
Utilization of transdermal patch varies from region to region due to which their market is diffused in nature. In both industrially developed and under developed countries their consumption is increasing significantly in past few years. US is one of the largest transdermal patch market across the globe followed by Europe. Investment in research and development allows the continuous entry of new products in US market due to which it has largest market shares across the globe. It is pioneer in this field and first patch was introduced in 1979 to treat motion sickness after its wide spread acceptance patches for angina, high blood pressure and hormone replacement therapy were introduced in US market. Over the year newer categories like smoking cessation, pain management, Parkinson’s disease, Alzheimer’s disease, ADHD and may others disease indications were added resulting in increased market size.
Clinical pipeline for transdermal patches is becoming strong and various novel therapeutics are at different stages of clinical trials which would enter in market in coming years. It is happening because pharmaceutical companies have identified their commercial potential due to which they are investing more toward research and development segment. Orally administrated drugs are not suitable for all patients as they have gastric reflex problem or may have other gastrointestinal diseases due to which bioavailability is limited. On the other, in blood they may interact with other substance causing reduced pharmacological effects. All these problems are not encountered by patients using the transdermal patches.
New principles are being deciphered and increasing emphasis on including more diseases treatment by transdermal patches is imperative for better health. Owing to increasing disease incidences, it has become necessary to take necessary steps to introduce innovative transdermal patches in global market. Oncology and autoimmune diseases are still untouched by them due to which significant opportunities are left untapped. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. On the other hand, nicotine patches and female contraceptive patches are highly developed and forms largest categories of transdermal patch segment. Disease indications will be increased in coming years and advancements in polymer science is expected to increase the innovation rates. With all these developments, the future of transdermal patch market seems to be optimistic.
“Global Transdermal Patch Market & Pipeline Insight 2015” Report Highlights:
- Mechanism of Transdermal Patch Drug Delivery
- Global Transdermal Patch Market Outlook
- Transdermal Patch Clinical Pipeline by Company, Indication & Phase
- Transdermal Patches in Clinical Pipeline: 96
- Marketed Transdermal Patches: 45
- Global Transdermal Patch Market Future Prospects
1. INTRODUCTION TO TRANSDERMAL PATCH
2. TYPES OF TRANSDERMAL PATCHES
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
3. MECHANISM OF TRANSDERMAL PATCH DRUG DELIVERY
4. ADVANTAGES OF TRANSDERMAL PATCH
5. GLOBAL TRANSDERMAL PATCH MARKET OUTLOOK
5.1 Current Market Scenario
5.2 Regional Trends
5.3 Transdermal Patch Clinical Pipeline Overview
6. GLOBAL TRANSDERMAL PATCH MARKET DYNAMICS
6.1 Favorable Market Parameters
6.2 Commercialization Challenges
7. GLOBAL TRANSDERMAL PATCH MARKET FUTURE PROSPECTS
8. GLOBAL TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Unknown
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase-I
8.6 Phase-I/II
8.7 Phase-II
8.8 Phase-III
8.9 Preregistration
8.10 Registered
9. MARKETED TRANSDERMAL PATCH BY COMPANY & INDICATION
10. SUSPENDED & DISCONTINUED TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
10.1 No Development Reported
10.2 Discontinued
10.3 Market withdrawal
10.4 Suspended
11. COMPETITIVE LANDSCAPE
11.1 3M Pharmaceuticals
11.2 Actavis
11.3 Ethical Holdings
11.4 GalaxoSmithKline
11.5 Johnson & Johnson
11.6 Novartis
11.7 Pfizer
11.8 Proctor & Gamble
11.9 ProStrakan
11.10 UCB pharmaceuticals
11.11 Vaxxas pharmaceutical
2. TYPES OF TRANSDERMAL PATCHES
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
3. MECHANISM OF TRANSDERMAL PATCH DRUG DELIVERY
4. ADVANTAGES OF TRANSDERMAL PATCH
5. GLOBAL TRANSDERMAL PATCH MARKET OUTLOOK
5.1 Current Market Scenario
5.2 Regional Trends
5.3 Transdermal Patch Clinical Pipeline Overview
6. GLOBAL TRANSDERMAL PATCH MARKET DYNAMICS
6.1 Favorable Market Parameters
6.2 Commercialization Challenges
7. GLOBAL TRANSDERMAL PATCH MARKET FUTURE PROSPECTS
8. GLOBAL TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Unknown
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase-I
8.6 Phase-I/II
8.7 Phase-II
8.8 Phase-III
8.9 Preregistration
8.10 Registered
9. MARKETED TRANSDERMAL PATCH BY COMPANY & INDICATION
10. SUSPENDED & DISCONTINUED TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
10.1 No Development Reported
10.2 Discontinued
10.3 Market withdrawal
10.4 Suspended
11. COMPETITIVE LANDSCAPE
11.1 3M Pharmaceuticals
11.2 Actavis
11.3 Ethical Holdings
11.4 GalaxoSmithKline
11.5 Johnson & Johnson
11.6 Novartis
11.7 Pfizer
11.8 Proctor & Gamble
11.9 ProStrakan
11.10 UCB pharmaceuticals
11.11 Vaxxas pharmaceutical
LIST OF FIGURES
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 3-1: Properties of Transdermal Therapeutics
Figure 3-2: Components of Transdermal Patch
Figure 3-3: Types of Permeation Enhancers
Figure 3-4: Schematic Representation of Iontophoresis
Figure 3-5: Mechanism of Scopolamine Transdermal Patch
Figure 3-6: Mechanism of Nicotine Transdermal Patch
Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 4-1: Issues with Traditional Drug Delivery Methods
Figure 4-2: Advantages of Transdermal Patch
Figure 4-3: Consistent Drug Supply by Transdermal Patch
Figure 5-1: Transdermal Patch Clinical Pipeline by Phase (%), 2015
Figure 5-2: Transdermal Patch Clinical Pipeline by Phase (Number), 2015
Figure 5-3: No Development Reported in Transdermal Patch Clinical Pipeline by Phase (%), 2015
Figure 5-4: No Development Reported in Transdermal Patch Clinical Pipeline by Phase (Number), 2015
Figure 5-5: Discontinued Transdermal Patch Clinical Pipeline by Phase (%), 2015
Figure 5-6: Discontinued Transdermal Patch Clinical Pipeline by Phase (Number), 2015
Figure 6-1: Drivers for Transdermal Patch
Figure 6-2: Transdermal Patch Market Commercialization Challenges
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 3-1: Properties of Transdermal Therapeutics
Figure 3-2: Components of Transdermal Patch
Figure 3-3: Types of Permeation Enhancers
Figure 3-4: Schematic Representation of Iontophoresis
Figure 3-5: Mechanism of Scopolamine Transdermal Patch
Figure 3-6: Mechanism of Nicotine Transdermal Patch
Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 4-1: Issues with Traditional Drug Delivery Methods
Figure 4-2: Advantages of Transdermal Patch
Figure 4-3: Consistent Drug Supply by Transdermal Patch
Figure 5-1: Transdermal Patch Clinical Pipeline by Phase (%), 2015
Figure 5-2: Transdermal Patch Clinical Pipeline by Phase (Number), 2015
Figure 5-3: No Development Reported in Transdermal Patch Clinical Pipeline by Phase (%), 2015
Figure 5-4: No Development Reported in Transdermal Patch Clinical Pipeline by Phase (Number), 2015
Figure 5-5: Discontinued Transdermal Patch Clinical Pipeline by Phase (%), 2015
Figure 5-6: Discontinued Transdermal Patch Clinical Pipeline by Phase (Number), 2015
Figure 6-1: Drivers for Transdermal Patch
Figure 6-2: Transdermal Patch Market Commercialization Challenges
